Stemina Biomarker Discovery operates in the biotechnology sector, specializing in in vitro toxicity testing and neurological disorder diagnostics. The company serves pharmaceutical, food, and consumer product industries by providing highly predictive human cell-based assays that offer an alternative to traditional animal testing. Stemina's core business units include Stemina, focused on toxicology, and NeuroPointDX, which targets the diagnosis and treatment of neurological disorders such as autism. Utilizing a shared metabolomics platform, Stemina's devTOX quickPredict and Cardio quickPredict assays identify developmental and cardiotoxicity potential of drug candidates and other compounds. The business model revolves around offering these predictive assays to clients, generating revenue through service fees and long-term contracts. Stemina's innovative approach aims to improve human health by providing more accurate and ethical testing methods.

Keywords: in vitro toxicity, human cell-based assays, metabolomics, developmental toxicity, cardiotoxicity, neurological disorders, autism diagnosis, pharmaceutical testing, food safety, consumer product safety.